Thrombin-Activatable Fibrinolysis Inhibitor (TAFI, Plasma Procarboxypeptidase B, Procarboxypeptidase R, Procarboxypeptidase U)

Author： Bouma B.N. Marx P.F. Mosnier L.O. Meijers J.C.M.

Publisher： Elsevier

ISSN： 0049-3848

Source： Thrombosis Research, Vol.101, Iss.5, 2001-03, pp. : 329-354

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis

By Wang Xinkang Smith Patricia Hsu Mei-Yin Tamasi Joseph Bird Eileen Schumacher William

Journal of Thrombosis and Thrombolysis, Vol. 23, Iss. 1, 2007-02 ,pp. : 41-49

Springer Publishing Company

Access to resources Recommend Favorite

Thrombin-Activatable Fibrinolysis Inhibitor in Breast Cancer Patients

Medical Principles and Practice, Vol. 20, Iss. 4, 2011-05 ,pp. : 332-335

Karger

Access to resources Recommend Favorite

Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Levels in Hypertensive Patients and a Comparison of the Effects of Amlodipine and Ramipril on TAFI Levels

By Ozkan Gulsum

Clinical and Experimental Hypertension, Vol. 35, Iss. 2, 2013-04 ,pp. : 134-140

Informa Healthcare

Access to resources Recommend Favorite

Activity and Antigen Levels of Thrombin-Activatable Fibrinolysis Inhibitor in Plasma of Patients With Disseminated Intravascular Coagulation

By Watanabe R. Wada H. Watanabe Y. Sakakura M. Nakasaki T. Mori Y. Nishikawa M. Gabazza E.C. Nobori T. Shiku H.

Thrombosis Research, Vol. 104, Iss. 1, 2001-10 ,pp. : 1-6

Elsevier

Access to resources Recommend Favorite

Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism

By Erem Cihangir

Endocrine Journal, Vol. 35, Iss. 1, 2009-02 ,pp. : 75-80

Humana Press, Inc

Access to resources Recommend Favorite